Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.
We recently published a list of the 10 Best Drug Stocks to Buy Now. In this article, we are going to take a look at where Eli ...
Summit Therapeutics (NASDAQ: SMMT), and Vertex Pharmaceuticals (NASDAQ: VRTX) could trounce the market in 2025. David Jagielski (Eli Lilly): For years, Eli Lilly has been a fairly safe bet to ...
WashU Medicine-led trial evaluating investigational drug from Eli Lilly and Company aims to stop disease before symptoms ...
For this list, we first used a stock screener to identify ... (see more details here). Eli Lilly and Company (NYSE:LLY) is a pharmaceutical company that manufactures and develops a wide range ...
Eli Lilly and Company (NYSE:LLY) develops ... % revenue growth in fiscal 2024 compared to fiscal 2023, exceeding its first-time guidance by $4 billion. It also made substantial progress across ...
So far in 2025, the year’s biggest cultural events have served as launchpads for several of the industry's latest cancer ...
Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Zepbound® (tirzepatide) as the first and only prescription medicine for adults with moderate ...
After pre-announcing that its full-year revenue would come in below its original guidance, Eli Lilly ... The company is expected to have 1.6 times as many incretin saleable doses in the first ...
For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...